Abivax ADS (ABVX) traded lower on Wednesday, April 29, 2026, down about 3% to $106.48, extending a recent pullback. A scan of company disclosures shows no new Abivax press release or filing timed to explain a sudden, stock-specific catalyst today, suggesting the decline is mainly a trading-driven move rather than a new fundamental headline. (ir.abivax.com)

The stock’s backdrop remains its most recent company update on March 23, 2026 (full-year 2025 results and business updates), which reiterated ongoing late-stage development work and noted the DSMB’s March 18, 2026 safety review for the Phase 3 ABTECT-UC maintenance study reported no new safety signals. With those details already absorbed by the market, incremental price action can be sensitive to broader biotech sentiment and near-term profit-taking after sharp prior gains. (ir.abivax.com)

The next high-impact catalyst for ABVX is clinical: top-line results from the Phase 3 ABTECT-UC maintenance program are expected in 2026, which can drive large moves as investors reprice approval odds and commercial potential. In the nearer term, attention will also be on any additional program updates highlighted in the company’s 2026 outlook, plus any shifts in ratings/targets that could influence momentum. (ir.abivax.com)